著者名,論文名,雑誌名,ISSN,出版者名,出版日付,巻,号,ページ,URL,URL(DOI)
Caicun Zhou and Yi Long Wu and Xiaoqing Liu and Changli Wang and Gongyan Chen and Ji Feng Feng and Shucai Zhang and Jie Wang and Songwen Zhou and Shengxiang Ren and Shun Lu and Li Zhang and Cheng-ping Hu and Yi Luo and Lei Chen and Ming Ye and Jianan Huang and Xiuyi Zhi and Yiping Zhang and Qingyu Xiu,"Overall survival (OS) results from OPTIMAL (CTONG0802), a phase III trial of erlotinib (E) versus carboplatin plus gemcitabine (GC) as first-line treatment for Chinese patients with <i>EGFR</i> mutation-positive advanced non-small cell lung cancer (NSCLC).",Journal of Clinical Oncology,0732-183X,American Society of Clinical Oncology (ASCO),2012-05-20,30,15_suppl,7520-7520,https://cir.nii.ac.jp/crid/1361418518529278464,https://doi.org/10.1200/jco.2012.30.15_suppl.7520